Prevention of Recurrent Episodes of Depression With Venlafaxine ER in a 1-Year Maintenance Phase From the PREVENT Study
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: To test the long-term efficacy and safety of venlafaxine extended-release (ER) in preventing recurrence in patients with major depression. METHOD: This multiple-phase study, entitled "Prevention of Recurrent Episodes of Depression With Venlafaxine for Two Years" (PREVENT), was conducted from December 2000 through July 2005 in patients with recurrent unipolar depression (DSM-IV) who were initially randomly assigned to double-blind treatment with venlafaxine ER (75 mg/day to 300 mg/day) or fluoxetine (20 mg/day to 60 mg/day) for 10 weeks of acute treatment. Responders then received 6 months of continuation treatment. Those who remained responders were then enrolled into a 12-month maintenance period. Venlafaxine ER responders were randomly assigned to receive double-blind treatment with venlafaxine ER or placebo. Fluoxetine responders were not randomly assigned but continued taking fluoxetine in order to maintain the blind during the maintenance study. Time to recurrence of depression (17-item Hamilton Rating Scale for Depression total score > 12 and < 50% reduction from acute phase baseline) with venlafaxine ER versus that of placebo were compared. RESULTS: The efficacy evaluable sample consisted of 129 patients in each group. The mean daily dose of venlafaxine ER was 224.7 mg (SD = 66.7). The cumulative probability of recurrence through 12 months, based on the primary definition, was 23.1% (95% CI = 15.3 to 30.9) for venlafaxine ER and 42.0% (95% CI = 31.8 to 52.2) for placebo (p = .005, log-rank test). CONCLUSION: Patients who had been successfully treated with venlafaxine ER during acute and continuation therapy were significantly less likely to experience recurrence with venlafaxine ER than with placebo over a 12-month maintenance treatment period. CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov identifier NCT00046020.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Kocsis 2007 (n = 336) reported that one participant in the continuation group experienced suicidal thoughts; study authors considered this not related to treatment.”
From Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults (2021) · cites this paper as Kocsis 2007
In the citing paper
“No suicide attempts during the trial were reported.”
From Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults (2021) · cites this paper as Kocsis 2007
In the citing paper
“Suicidal ideations were also reported by one participant in the discontinuation group.”
From Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults (2021) · cites this paper as Kocsis 2007
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
(1976) · Medical Entomology and Zoology · Cited by 8,899
(1993) · PubMed · Cited by 1,900
Assessment of social adjustment by patient self report.
Weissman, M. M. (1976) · Archives of General Psychiatry · doi:10.1001/archpsyc.1976.01770090101010 · Cited by 1,782
Keller, M. B. (1987) · Archives of General Psychiatry · doi:10.1001/archpsyc.1987.01800180050009 · Cited by 1,643
Self-citationThree-Year Outcomes for Maintenance Therapies in Recurrent Depression
Frank, E. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810240013002 · Cited by 1,297
Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12599-8 · Cited by 945
The inventory for depressive symptomatology (IDS): Preliminary findings
John Rush, A., Giles, D. E., Schlesser, M. A., Fulton, C. L., Weissenburger, J., & Burns, C. (1986) · Psychiatry Research · doi:10.1016/0165-1781(86)90060-0 · Cited by 918
Anderson, I., Ferrier, I., Baldwin, R., Cowen, P., Howard, L., Lewis, G., Matthews, K., McAllister-Williams, R., Peveler, R., Scott, J., et al. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107088441 · Cited by 908
Cited by
PRACTICE GUIDELINE FOR THE Treatment of Patients With Major Depressive Disorder
Gelenberg, A. J., Freeman, P. B., Markowitz, J. C., Rosenbaum, J. F., Thase, M. E., Trivedi, M. H., & Rhoads, R. S. (2010) · Cited by 1,521
Self-citationFluoxetine versus other types of pharmacotherapy for depression
Magni, L. R., Purgato, M., Gastaldon, C., Papola, D., Furukawa, T. A., Cipriani, A., & Barbui, C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004185.pub3 · Cited by 252
Sim, K., Lau, W. K., Sim, J., Sum, M. Y., & Baldessarini, R. J. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv076 · Cited by 218
“, 2005, 2009) than with pharmacotherapies (Montgomery and Dunbar, 1993; M Fava et al., 1998; Lepine et al., 2004; Keller et al., 2007a; 2007b; Kocsis et al., 2007; Kuyken et al., 2008; Bondolfi et al., 2010; Kelin et al., 2010; Mathew et al., 2010; Thase et al., 2011).”
BackgroundLi, C.-T., Lin, C.-P., Chou, K.-H., Chen, I.-Y., Hsieh, J.-C., Wu, C.-L., Lin, W.-C., & Su, T.-P. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2009.11.021 · Cited by 213
“This is why remission without residual symptoms, rather than a 50% improvement on a depression rating scale, is now regarded as an optimal outcome in treating depression (Bakish, 2001; Israel, 2006; Kocsis et al., 2007).”
Bauer, M., Severus, E., Köhler, S., Whybrow, P. C., Angst, J., Möller, H.-J., & on behalf of the Wfsbp Task Force on Treatment Guidelines for Unipolar Depressive Disorders (2015) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2014.1001786 · Cited by 199
“Fluoxetine responders were not randomly assigned but continued taking fl uoxetine in order to maintain the blind during the maintenance study (Kocsis et al. 2007).”
BackgroundSerotonin and Norepinephrine Reuptake Inhibitors
Shelton, R. C. (2018) · Handbook of Experimental Pharmacology · doi:10.1007/164_2018_164 · Cited by 171
Self-citationKato, M., Hori, H., Inoue, T., Iga, J., Iwata, M., Inagaki, T., Shinohara, K., Imai, H., Murata, A., Mishima, K., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0843-0 · Cited by 152
Why antidepressants are not antidepressants: STEP‐BD, STAR*D, and the return of neurotic depression
Nassir Ghaemi, S. (2008) · Bipolar Disorders · doi:10.1111/j.1399-5618.2008.00639.x · Cited by 144
Kishi, T., Ikuta, T., Sakuma, K., Okuya, M., Hatano, M., Matsuda, Y., & Iwata, N. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01824-z · Cited by 136
Craighead, W. E., & Dunlop, B. W. (2014) · Annual Review of Psychology · doi:10.1146/annurev.psych.121208.131653 · Cited by 128
Keller, M. B., Trivedi, M. H., Thase, M. E., Shelton, R. C., Kornstein, S. G., Nemeroff, C. B., Friedman, E. S., Gelenberg, A. J., Kocsis, J. H., Dunner, D. L., et al. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0812 · Cited by 116
Self-citationAndrews, P. W., Kornstein, S. G., Halberstadt, L. J., Gardner, C. O., & Neale, M. C. (2011) · Frontiers in Psychology · doi:10.3389/fpsyg.2011.00159 · Cited by 107
Self-citationVan Leeuwen, E., van Driel, M. L., Horowitz, M. A., Kendrick, T., Donald, M., De Sutter, A. I., Robertson, L., & Christiaens, T. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013495.pub2 · Cited by 90
Liebowitz, M., Lam, R. W., Lepola, U., Datto, C., Sweitzer, D., & Eriksson, H. (2010) · Depression and Anxiety · doi:10.1002/da.20740 · Cited by 86
“In an olanzapine/fluoxetine combination study, improvements in MADRS and CGI-S scores were maintained,([36]) whereas in a venlafaxine study, improvements in HAM-A and CGI-S scores were maintained.([37]) During the open-label stabilization phase, the most common reason for discontinuation was an AE, and the most common…”
ResultLydiatt, W. M. (2013) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2013.3371 · Cited by 82
Solving the Antidepressant Efficacy Question: Effect Sizes in Major Depressive Disorder
Vöhringer, P. A., & Ghaemi, S. N. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.11.019 · Cited by 82
Pharmacotherapy of Mood Disorders
Thase, M. E., & Denko, T. (2008) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.2.022305.095301 · Cited by 79
Self-citationRelapse rates with long‐term antidepressant drug therapy: a meta‐analysis
Williams, N., Simpson, A. N., Simpson, K., & Nahas, Z. (2009) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.1033 · Cited by 74
“All of the studies satisfied the 24 week time point, 9 out of 11 studies satisfied the 48 week time point (Gilaberte et al., 2001; Hochstrasser et al., 2001; Keller et al., 1998; Klysner et al., 2002; Kocsis et al., 2007; Kornstein et al., 2006; Lepine et al., 2004; McGrath et al., 2006; Perahia et al., 2006; Reynolds…”
BackgroundMethodResultInfluentialKornstein, S. G., Pedersen, R. D., Holland, P. J., Nemeroff, C. B., Rothschild, A. J., Thase, M. E., Trivedi, M. H., Ninan, P. T., & Keller, M. B. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m07841 · Cited by 46
Self-citationStudies of Long-Term Use of Antidepressants: How Should the Data from Them be Interpreted?
El-Mallakh, R. S., & Briscoe, B. (2012) · CNS Drugs · doi:10.2165/11599450-000000000-00000 · Cited by 36
Trivedi, M. H., Dunner, D. L., Kornstein, S. G., Thase, M. E., Zajecka, J. M., Rothschild, A. J., Friedman, E. S., Shelton, R. C., Keller, M. B., Kocsis, J. H., et al. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.04.011 · Cited by 36
Self-citationRickels, K., Montgomery, S. A., Tourian, K. A., Guelfi, J. D., Pitrosky, B., Padmanabhan, S. K., Germain, J.-M., Leurent, C., & Brisard, C. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181c94c4d · Cited by 33
Thase, M. E., Gelenberg, A. J., Kornstein, S. G., Kocsis, J. H., Trivedi, M. H., Ninan, P. T., Li, T., Pedersen, R., & Keller, M. B. (2010) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2010.07.009 · Cited by 28
“The results from the analyses comparing venlafaxine ER and placebo have been published elsewhere (Keller et al., 2007a,b; Kocsis et al., 2007).”
BackgroundMethodResultInfluentialSelf-citation(2014) · Europe PMC (PubMed Central) · Cited by 24
Gelenberg, A. J., Dünner, D. L., Rothschild, A. J., Pedersen, R., Dorries, K. M., & Ninan, P. T. (2013) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0b013e318288d298 · Cited by 26
“The PREVENT study included four phases: a 10-week acute phase, a 6-month continuation phase, and two consecutive 12-month maintenance phases (Keller et al., 2007a, 2007b; Kocsis et al., 2007).”
MethodSelf-citationWiesinger, T., Kremer, S., Bschor, T., & Baethge, C. (2023) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13541 · Cited by 30
Kornstein, S. G. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.5.737 · Cited by 21
Self-citationKornstein, S. G., Kocsis, J. H., Ahmed, S., Thase, M. E., Friedman, E. S., Dunlop, B. W., Yan, B., Pedersen, R., Ninan, P. T., Li, T., et al. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328314e2cb · Cited by 19
“…remaining recurrence-free presented in the primary analysis of the PREVENT study data [i.e., year 1: venlafaxine ER: 77%; placebo: 58%; P = 0.005 (Kocsis et al., 2007); year 2: venlafaxine ER: 92%; placebo: 55%; P < 0.001 (Keller et al., 2007a); combined maintenance phase: venlafaxine ER: 71%;…”
InfluentialSelf-citationBaldessarini, R. J., Lau, W. K., Sim, J. Z. T., Sum, M. Y., & Sim, K. (2016) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw092 · Cited by 20
Increased Rate of Non-Right-Handedness in Patients With Bipolar Disorder
Nowakowska, C., Sachs, G. S., Zarate, C. A., Marangell, L. B., Calabrese, J. R., Goldberg, J. F., & Ketter, T. A. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0522g · Cited by 20
Continuation treatment of major depressive disorder: is there a case for duloxetine?
Norman, T. R., & Olver, J. S. (2010) · Drug Design Development and Therapy · doi:10.2147/dddt.s4358 · Cited by 19
“27 Recently, venlafaxine has demonstrated superiority over placebo for relapse prevention at both one year 28 and two year 29,30 follow-up periods.”
Recovery and subsequent recurrence in patients with recurrent major depressive disorder
Dunlop, B. W., Holland, P., Bao, W., Ninan, P. T., & Keller, M. B. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.03.002 · Cited by 15
“randomized patients in the intent-to-treat (ITT) population of maintenance phase A (ie, all patients who took ≥1 dose of study medication and had ≥1 post-randomization HAM-D17 assessment) except those who were affected by a drug-dispensing issue, described previously (Kocsis et al., 2007).”
BackgroundMethodSelf-citationZhou, D., Lv, Z., Shi, L., Zhou, X., Lin, Q., Chen, X., Wan, L.-Y., Li, Y., Ran, L., Huang, Y., et al. (2020) · Psychological Medicine · doi:10.1017/s0033291720001610 · Cited by 14
“…Hochstrasser et al., 2001; Kamijima, Burt, Cohen, Arano, & Hamasaki, 2006; Kasper, Volz, Moller, Dienel, & Kieser, 2008; Keller et al., 1998, 2005; Kocsis et al., 2007; Liebowitz et al., 2010; McGrath et al., 2006; Montgomery & Dunbar, 1993; Montgomery et al., 1988; Montgomery, Entsuah, Hackett,…”
Delcourte, S., Etiévant, A., & Haddjeri, N. (2021) · Progress in brain research · doi:10.1016/bs.pbr.2021.01.002 · Cited by 18
A 10-Month, Open-Label Evaluation of Desvenlafaxine in Outpatients With Major Depressive Disorder
Tourian, K. A., Pitrosky, B., Padmanabhan, S. K., & Rosas, G. R. (2011) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.10m00977blu · Cited by 15
High-dose desvenlafaxine in outpatients with major depressive disorder
Ferguson, J. M., Tourian, K. A., & Rosas, G. R. (2012) · CNS Spectrums · doi:10.1017/s1092852912000508 · Cited by 13
Self-citationArano, I., Sugimoto, T., Hamasaki, T., & Ohno, Y. (2010) · BMC Medical Research Methodology · doi:10.1186/1471-2288-10-33 · Cited by 13
“Table 1 provides a summary of the design and rates of relapse in MDD patients from several recent randomized withdrawal studies [1-5].”
BackgroundLong-Term Treatment of Mood Disorders
Nolen, W. A., & Grunze, H. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-405170-6.00004-x · Cited by 12
Aripiprazole Joins the Family of Second-Generation Mood Stabilizers
RYBAKOWSKI, J. K. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0522b · Cited by 10
Kelin, K., Berk, M., Spann, M., Sagman, D., Raskin, J., Walker, D., & Perahia, D. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02374.x · Cited by 11
McGoldrick, A., Byrne, H., & Cadogan, C. A. (2023) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-023-01602-z · Cited by 10
Oakes, T. M. M., Dellva, M. A., Waterman, K., Greenbaum, M., Poppe, C. J., Goldberger, C., AHL, J. S. B., & David, P. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1037732 · Cited by 11
Zainal, N. H. (2023) · Psychological Medicine · doi:10.1017/s0033291723003306 · Cited by 11
Kremer, S., Wiesinger, T., Bschor, T., & Baethge, C. (2023) · Psychotherapy and Psychosomatics · doi:10.1159/000533494 · Cited by 12
Boyer, P., Vialet, C., Hwang, E., & Tourian, K. A. (2015) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.14m01711 · Cited by 9
Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression
Gartlehner, G., Hansen, R. A., Morgan, L. C., Thaler, K. J., Lux, L. J., Noord, M. V., Mager, U., Gaynes, B. N., Thieda, P., Strobelberger, M., et al. (2011) · Cited by 8
Zaccoletti, D., Mosconi, C., Gastaldon, C., Benedetti, L., Gottardi, C., Papola, D., Ponzi, O., Purgato, M., Naudet, F., Cristea, I. A., et al. (2025) · The Lancet Psychiatry · doi:10.1016/s2215-0366(25)00330-x · Cited by 13
A Case of Sodium Oxybate Treatment of Tardive Dyskinesia and Bipolar Disorder
Berner, J. E. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0522a · Cited by 8
Watanabe, K., Thase, M. E., Kikuchi, T., Tsuboi, T., Asami, Y., Pappadopulos, E. A., Zhang, M., Boucher, M., & Kornstein, S. G. (2017) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000183 · Cited by 3
“In patients enrolled in the PREVENT study, venlafaxine ER treatment was associated with a significant improvement in depression symptoms and psychosocial functioning, and also showed efficacy in reducing the likelihood of loss of functioning and recurrence of depression, both for the full 75–300mg/day dose range (Kell…”
BackgroundResultInfluentialSelf-citationPsychopharmakotherapie – klinisch-empirische Grundlagen
Volz, H., Kasper, S. F., & Möller, H. (2017) · Springer eBooks · doi:10.1007/978-3-662-49295-6_31 · Cited by 3
Laux, G., & Klimke, A. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_414 · Cited by 2
Hamamura, T., Kodama, M., & Harada, T. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0522c · Cited by 2
Laux, G., & Klimke, A. (2022) · Springer eBooks · doi:10.1007/978-3-319-56015-1_414-1 · Cited by 2
Risk of Recurrence of Depression During Long-Term Antidepressant Treatment
Sloan, D. M., & Kornstein, S. G. (2007) · CNS Spectrums · doi:10.1017/s1092852900028200 · Cited by 1
Self-citationCurrent awareness in human psychopharmacology
(2008) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.888 · Cited by 1
BOLAND, R. J., Gaud, K. G., & Keller, M. B. (2015) · Wiley eBooks · doi:10.1002/9781118753378.ch103 · Cited by 1
Self-citationKato, M., Hori, H., & Tajika, A. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02023-0 · Cited by 1
McIntyre, R. S., Fayyad, R. S., Guico‐Pabia, C. J., & Boucher, M. (2015) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.14m01681
Jureidini, J. N., & Mintzes, B. J. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0522e
Keller, M. B., & Kocsis, J. H. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0522f
Self-citationSantone, G., Bellantuono, C., & Psichiatrica, C. (2009)
Perugi, G., Romano, A. M., & Tusini, G. L. (2007) · CINECA IRIS Institutial research information system (University of Pisa)
Psychopharmakotherapie – klinisch-empirische Grundlagen
Volz, H., Kasper, S. F., & Möller, H. ‐. (2015) · Springer eBooks · doi:10.1007/978-3-642-45028-0_31-1
Prescorn, S. H. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0522d
Дифференцированная психофармакотерапия рекуррентного депрессивного расстройства на этапе ремиссии
Zakharova, N. V. (2015) · Psikhiatriya · doi:10.30629/2618-6667-2015-67-32-41 · Cited by 1
Chapter 19. Venlafaxine and Desvenlafaxine
Thase, M. E. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as19 · Cited by 1
Self-citationPsychopharmakotherapie – klinisch-empirische Grundlagen
Kasper, S. F., Hasan, A., & Möller, H. (2026) · Springer Reference Medizin · doi:10.1007/978-3-642-45028-0_31-2
Metadata
- Authors
- Kocsis, J. H., Thase, M. E., Trivedi, M. H., Shelton, R. C., Kornstein, S. G., Nemeroff, C. B., Friedman, E. S., Gelenberg, A. J., Dunner, D. L., Hirschfeld, R. M. A., Rothschild, A. J., Ferguson, J. M., Schatzberg, A. F., Zajecka, J. M., Pedersen, R. D., Yan, B., Ahmed, S., Musgnung, J., Ninan, P. T., & Keller, M. B.
- Affiliations
- Cornell University (US)
- University of Pennsylvania (US)
- The University of Texas Southwestern Medical Center (US)
- Vanderbilt University (US)
- Virginia Commonwealth University (US)
- Emory University (US)
- University of Pittsburgh (US)
- University of Arizona (US)
- The University of Texas Medical Branch at Galveston (US)
- University of Massachusetts Chan Medical School (US)
- University of Utah (US)
- Stanford University (US)
- Rush University (US)
- Pfizer (United States) (US)
- Brown University (US)
- ORCID
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2007-07-15
- Volume
- 68
- Issue
- 07
- Pages
- 1014-1023
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2073228294
- Semantic Scholar
- 8dc9020e6c71f6bbcf5739a447273d8974bdfed8
- Cited by
- 67
- References
- 33
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2023: 5 · 2022: 3 · 2021: 2 · 2020: 2 · 2018: 1 · 2017: 2 · 2016: 1 · 2015: 9 · 2014: 1 · 2013: 4 · 2012: 3
- FWCI
- 5.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- eScholarship@UMassChan (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- venlafaxine extended release, depression recurrence prevention, major depressive disorder, maintenance therapy, fluoxetine, antidepressant efficacy, long-term safety, PREVENT study
- MeSH terms
- Venlafaxine Hydrochloride, Adult, Cyclohexanols, Delayed-Action Preparations, Major Depressive Disorder, Double-Blind Method, Drug Administration Schedule, Female, Humans, Male, Outpatients, Selective Serotonin Reuptake Inhibitors, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.